# Maha Hussain

Source: https://onco.cc/people/maha-hussain/  
OnCo record `maha-hussain` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led PROSPER and the PROfound survival analysis, and settled the intermittent hormone therapy question with SWOG 9346.

## Summary

Maha Hussain led SWOG 9346, the trial that showed intermittent androgen deprivation is not non-inferior to continuous therapy in metastatic prostate cancer, and was principal investigator of PROSPER (enzalutamide in non-metastatic CRPC) and first author of the PROfound overall survival report establishing olaparib in HRR-mutant disease. She chairs the SWOG GU committee's prostate programme.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: prostate; swog; parp
- Role: Genevieve E. Teuton Professor of Medicine and Deputy Director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Specialisms: Prostate cancer; PARP inhibitors; Androgen deprivation strategies; Cooperative-group trials

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Maha_H._Hussain
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Hussain%20M%5BAuthor%5D%20prostate%20olaparib%20OR%20enzalutamide

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Androgen deprivation & AR pathway inhibitors](https://onco.cc/technologies/androgen-deprivation/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/), [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- institutions: [Robert H. Lurie Comprehensive Cancer Center of Northwestern University](https://onco.cc/institutions/northwestern-lurie/)
- trials: [PROfound](https://onco.cc/trials/profound/), [PROSPER](https://onco.cc/trials/prosper/)

---
JSON: https://onco.cc/api/v1/entities/maha-hussain.json